A new round of RPB grants is now open! Click here to view our available grants.
Research to Prevent Blindness’ mission and leadership makes the eyecare of today—and tomorrow—possible.
For decades, RPB grants have provided funding to create new discoveries in vision science. Learn about our current grants, as well as our exceptional grantees.
What do we know about common eye diseases? Find out here, in RPB’s new Learning Center for patients and families.
Visit our Media Center for timely updates—in text and video formats—on emerging research and vision science news.
Your support makes our vision-saving work possible! There are many ways to engage with RPB.
Dry eye is a chronic medical condition that develops when the eye's tear film does not lubricate and protect the eye's outer surface.
There are RPB awardees at all stages of a research career, studying all conditions that damage sight. At any given moment, we have hundreds of active awardees across the U.S. working hard on sight-saving research.
RPB currently funds 32 Departmental grantees, who are responsible for much of the outstanding ophthalmology research happening around the country. These departments have shown excellence in their science, leadership and impact.
Search the grantee you're looking for by name.
Grant Type:
Individual
Award Name:
Catalyst Award for Innovative Research Approaches for Age-Related Macular Degeneration
Year:
2019
Amount:
$300,000.00
Research Area:
Will study retinal pigment epithelium (RPE) cell damage (a known precursor to AMD), with the goal of learning about the mechanisms that initiate RPE damage and subsequently relate these processes to the onset of AMD.
2014
$250,000.00
Career Development Award
2009
$200,000.00
Understanding cholesterol homeostasis in the retinal pigment endothelium and assessing whether cholesterol modifying drugs like statins will be beneficial to the treatment of AMD.
*Grant Amounts Listed Reflect Awards That Were Approved By The RPB Board of Trustees
*Grantees Shown Below Are For The Current Grant Year Only.